Towards a mission-oriented approach to cancer in Europe: an unmet need in cancer research policy.
cancer
cancer continuum
mission-oriented approach
network of centres
scientific, social and economic impact
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
15
01
2019
accepted:
15
01
2019
pubmed:
19
1
2019
medline:
30
11
2019
entrez:
19
1
2019
Statut:
ppublish
Résumé
Today, cancer is a significant challenge for society, healthcare systems and the growing number of affected patients and their families. This article argues that new paradigms and conditions for responsible science and innovation policy across the European Union (EU) require (i) the collective action of Research & Development institutions, (ii) a system approach to health systems, higher education and patient organizations, and (iii) new initiatives to encourage international cooperation across an enlarged Europe; no single country can successfully fight the disease(s) on its own. Recently, a cancer mission was proposed (Celis and Pavalski, ), the origins of which are rooted in the continuous efforts of the research community, cancer patient organizations, member states and the European Commission during nearly two decades to address the fragmentation and lack of coordination of European cancer research; these efforts led to the creation of Cancer Core Europe and Cancer Prevention Europe, consortia aimed at linking therapeutic and prevention geometries. Ultimately, the platform/infrastructure will be composed of networks of Comprehensive Cancer Centres and cancer research centres across Europe to reach the critical mass of expertise, patients and collaborative portfolio of projects that are necessary to promote science-driven and social innovations in the era of personalized (precision) cancer medicine. Employing a mission-oriented approach to achieve the goal of ensuring a long life expectancy for three out of four cancer patients by 2030 is likely to have a particularly positive impact on the way European citizens' value science and knowledge. It will change the lives of many families across Europe and beyond and should be oriented to ensure that Europe is at the forefront when it comes to quality of life. It is our collective responsibility to ensure that not a single person or region in Europe is left behind.
Identifiants
pubmed: 30657635
doi: 10.1002/1878-0261.12452
pmc: PMC6396358
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
502-510Informations de copyright
© 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Références
Mol Oncol. 2008 Jun;2(1):10-1
pubmed: 19383323
EMBO Rep. 2017 Nov;18(11):1873-1874
pubmed: 29021205
Mol Oncol. 2014 May;8(3):447-57
pubmed: 24726457
Angew Chem Int Ed Engl. 2003 Sep 29;42(37):4434-9
pubmed: 14520738
Mol Oncol. 2019 Mar;13(3):511-516
pubmed: 30811840
Mol Oncol. 2019 Mar;13(3):521-527
pubmed: 30657633
Mol Oncol. 2019 Mar;13(3):653-666
pubmed: 30657631
Mol Oncol. 2019 Mar;13(3):543-548
pubmed: 30628170
Mol Oncol. 2009 Feb;3(1):5-8
pubmed: 19383361
Tumori. 2008 Mar-Apr;94(2):164-71
pubmed: 18564602
Oncologist. 2012;17(10):e26-32
pubmed: 23104172
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Mol Oncol. 2019 Mar;13(3):648-652
pubmed: 30677237
Mol Oncol. 2017 Dec;11(12):1661-1672
pubmed: 29024497
Mol Oncol. 2018 Nov;12(11):1829-1837
pubmed: 30241109
Eur J Cancer. 2014 Nov;50(16):2745-6
pubmed: 25263570
Mol Oncol. 2019 Mar;13(3):614-618
pubmed: 30628155